Characters | mOS (months) | HR (95% CI) | p value |
---|---|---|---|
Gender | |||
 Male vs. Female | 24.4 vs. 13.4 | 0.563(0.302,1.048) | 0.070 |
Age | |||
 < 60 vs. > 60 | 15.9 vs. 22.6 | 1.354(0.775,2.364) | 0.287 |
Stage | |||
 IV vs. III | 18.4 vs. 26.6 | 1.388(0.647,2.976) | 0.399 |
Histology | |||
 Adenocarcinoma vs. Squamous | 16.1 vs. 26.0 | 1.550(0.874,2.749) | 0.134 |
Smoke | |||
 Yes vs. No | 22.4 vs. 16.6 | 0.987(0.566,1.723) | 0.964 |
Brain metastasis | |||
 Yes vs. No | 13.3 vs. 24.4 | 1.961(1.087,3.540) | 0.025* |
Liver metastasis | |||
 Yes vs. No | 13.4 vs. 24.4 | 2.260(1.194,4.276) | 0.012* |
Bone metastasis | |||
 Yes vs. No | 15.4 vs. 26.0 | 2.021(1.152,3.543) | 0.014* |
Pleural effusion | |||
 Yes vs. No | 15.0 vs. 22.4 | 1.816(0.893,3.692) | 0.100 |
Treatment lines | |||
 1line vs. 2 lines vs. ≥ 3 linesa | NA vs. 24.4 vs. 14.7 | 0.446(0.106, 1.877) | 0.271 |
0.535(0.296, 0.969) | 0.039* | ||
PDL1 expression | |||
 Negative vs. Positive | 16.6 vs. 22.4 | 1.157(0.663,2.020) | 0.608 |
 Negative vs. Low. vs. Higha | 16.6 vs. 18.2 vs. 26.8 | 1.357 (0.614,3.001) | 0.451 |
1.291 (0.543,3.071) | 0.563 | ||
Gene mutation | |||
 Wild vs. EGFR | 22.6 vs. 12.7 | 0.485(0.249,0.945) | 0.033* |
 Wild vs. EGFR vs. KRASa | 18.6 vs. 12.7 vs. 24.4 | 1.688(0.683, 4.172) | 0.257 |
3.029(1.145,8.011) | 0.026 |